0000000000621602

AUTHOR

Annett Mueller

showing 4 related works from this author

Analysis of Antiproliferative and Chemosensitizing Effects of Sunitinib on Human Esophagogastric Cancer Cells: Synergistic Interaction With Vandetani…

2009

The receptor tyrosine kinases (RTKs), epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor 1-3 (VEGFR1-3), are frequently expressed in gastric cancer and are putative therapeutic targets in this disease. We have investigated the anti-proliferative and chemosensitizing properties of the multitargeted small-molecule RTK inhibitors sunitinib and vandetanib in a panel of 4 human gastric and esophageal cancer cell lines. In the 1st instance, the expression of potential targets of these small-molecule inhibitors was examined by reverse transcriptase-polymerase chain reaction, western blotting, and flow cytometry. EGFR mRNA and protein was detected in all cases, …

Cancer ResearchUmbilical VeinsIndolesEsophageal NeoplasmsApoptosisVandetanibTyrosine-kinase inhibitorReceptor tyrosine kinasechemistry.chemical_compoundPiperidinesSunitinibMedicineDrug InteractionsEpidermal growth factor receptorPhosphorylationCells CulturedbiologySunitinibReverse Transcriptase Polymerase Chain ReactionDrug SynergismFlow CytometryErbB ReceptorsOncologyPhosphorylationDrug Therapy Combinationmedicine.drugSignal Transductionmedicine.medical_specialtymedicine.drug_classBlotting WesternAntineoplastic AgentsStomach NeoplasmsInternal medicineHumansPyrrolesPropidium iodideRNA MessengerProtein Kinase InhibitorsCell ProliferationVascular Endothelial Growth Factor Receptor-1business.industryCancermedicine.diseaseVascular Endothelial Growth Factor Receptor-3Vascular Endothelial Growth Factor Receptor-2EndocrinologychemistryCancer researchbiology.proteinQuinazolinesEndothelium VascularbusinessProto-Oncogene Proteins c-akt
researchProduct

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center bi…

2011

Abstract Background Cetuximab plus irinotecan/folinic acid/5-fluorouracil (5-FU) (IF) was evaluated as first-line treatment of patients with advanced gastric cancer and gastroesophageal junction tumors. Preplanned analyses of the influence of tumor biomarkers on treatment outcome were carried out. Patients and methods Patients received weekly cetuximab (400 mg/m2 on day 1, subsequently 250 mg/m2) plus irinotecan (80 mg/m2) and a 24-hour continuous infusion of folinic acid (200 mg/m2) and 5-FU (1500 mg/m2) on days 1, 8, 15, 22, 29 and 36 of a 50-day cycle, until progressive disease (PD). Results The most common grade 3/4 toxic effects in 49 patients were diarrhea (15%) and skin toxic effects…

AdultMalemedicine.medical_specialtyEsophageal Neoplasmsmedicine.drug_classMedizinLeucovorinPhases of clinical researchCetuximabAntibodies Monoclonal HumanizedIrinotecanAntimetaboliteGastroenterologyFolinic acidStomach NeoplasmsInternal medicineAntineoplastic Combined Chemotherapy ProtocolsMedicineHumansProgression-free survivalAgedCetuximabbusiness.industryAntibodies MonoclonalHematologyMiddle Agedmedicine.diseaseSurgeryIrinotecanTreatment OutcomeOncologyFluorouracilCamptothecinFemaleFluorouracilbusinessProgressive diseasemedicine.drugAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer

2013

Colon cancer (CC) is a leading cause of cancer mortality. Novel biomarkers are needed to identify CC patients at high risk of recurrence and those who may benefit from therapeutic intervention. The aim of this study is to investigate if miR-21 expression from RNA isolated from formalin-fixed paraffin-embedded (FFPE) tissue sections is associated with prognosis and therapeutic outcome for patients with CC. The expression of miR-21 was measured by quantitative reverse transcriptase-polymerase chain reaction in a Japanese cohort (stage I-IV, n = 156) and a German cohort (stage II, n = 145). High miR-21 expression in tumors was associated with poor survival in both the stage II/III Japanese (p …

OncologyCancer Researchmedicine.medical_specialtyColorectal cancerAdjuvant chemotherapybusiness.industryMicrosatellite instabilitymedicine.diseaseOncologyInternal medicinemicroRNACohortImmunologymedicineAdjuvant therapyBiomarker (medicine)Stage (cooking)businessInternational Journal of Cancer
researchProduct

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

2008

AIM: To gain mechanistic insights into the role played by epidermal growth factor receptor (EGFR) in the regulation of vascular endothelial growth factors (VEGFs) in colorectal cancer (CRC). METHODS: The impact of high-level expression of the growth factor receptors EGFR and VEGF receptor (VEGFR)3 and the VEGFR3 ligands VEGF-C and VEGF-D on disease progression and prognosis in human CRC was investigated in 108 patients using immunohistochemistry. Furthermore, the expression of the lymphangiogenic factors in response to the modulation of EGFR signalling by the EGFR-targeted monoclonal antibody cetuximab was investigated at the mRNA and protein level in human SW480 and SW620 CRC cell lines an…

AdultPathologymedicine.medical_specialtyColorectal cancerTransplantation HeterologousVascular Endothelial Growth Factor CVascular Endothelial Growth Factor DCetuximabAntineoplastic AgentsMice SCIDAntibodies Monoclonal HumanizedMiceGrowth factor receptorMice Inbred NODCell Line TumorMedicineAnimalsHumansEpidermal growth factor receptorneoplasmsAgedColorectal CancerAged 80 and overCetuximabbiologyintegumentary systembusiness.industryGastroenterologyVascular Endothelial Growth Factor DAntibodies MonoclonalGeneral MedicineMiddle Agedmedicine.diseaseVascular Endothelial Growth Factor Receptor-3digestive system diseasesLymphangiogenesisErbB ReceptorsVascular endothelial growth factor CCancer researchbiology.proteinImmunohistochemistryFemalebusinessColorectal NeoplasmsNeoplasm Transplantationmedicine.drugSignal Transduction
researchProduct